Cantor Fitzgerald Reaffirms Neutral Rating for Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF)‘s stock had its “neutral” rating reiterated by stock analysts at Cantor Fitzgerald in a report issued on Friday.

Several other brokerages have also weighed in on ZLDPF. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Four research analysts have rated the stock with a Strong Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $57.67 on Friday. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 4.22 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. Zealand Pharma A/S has a 12 month low of $49.98 and a 12 month high of $101.29. The company’s fifty day moving average price is $64.96 and its two-hundred day moving average price is $70.77.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. The company had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. As a group, research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.